Explore the HER2CLIMB-05 study's findings on tucatinib's impact on breast cancer progression-free survival, enhancing treatment options for pharmacists.
Erika Hamilton, MD
Advertisement
Articles by Erika Hamilton, MD
Compared with fulvestrant, vepdegestrant significantly extended progression-free survival and improved response rates.
Advertisement
Latest Updated Articles
HER2CLIMB-05: Tucatinib Added to Maintenance HP Extends PFS in HER2+ Metastatic Breast CancerPublished: December 11th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Unique Pharmacy Technician Career Ladder Meets the Needs of a Growing Profession
2
Emerging Therapeutic Strategies Transforming Myelofibrosis Care in 2026
3
Rocatinlimab Demonstrates Significant Efficacy and Safety in Phase 3 Trials for Moderate-to-Severe Atopic Dermatitis
4
Circulating Extracellular Vesicles Contribute to Heart Failure Pathogenesis in CKD
5